CA3090268A1 - Treatment of solid tumors using coenzyme q10 - Google Patents

Treatment of solid tumors using coenzyme q10

Info

Publication number
CA3090268A1
CA3090268A1 CA3090268A CA3090268A CA3090268A1 CA 3090268 A1 CA3090268 A1 CA 3090268A1 CA 3090268 A CA3090268 A CA 3090268A CA 3090268 A CA3090268 A CA 3090268A CA 3090268 A1 CA3090268 A1 CA 3090268A1
Authority
CA
Canada
Prior art keywords
dose
cancer
coq10
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3090268A
Other languages
English (en)
French (fr)
Inventor
Niven Rajin Narain
John Patrick Mccook
Paul Y. Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BERG LLC
Original Assignee
BERG LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BERG LLC filed Critical BERG LLC
Publication of CA3090268A1 publication Critical patent/CA3090268A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3090268A 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10 Abandoned CA3090268A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01
CA2875150A CA2875150C (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2875150A Division CA2875150C (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Publications (1)

Publication Number Publication Date
CA3090268A1 true CA3090268A1 (en) 2013-12-05

Family

ID=49673946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3090268A Abandoned CA3090268A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10
CA2875150A Active CA2875150C (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2875150A Active CA2875150C (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Country Status (16)

Country Link
US (3) US20140017317A1 (https=)
EP (1) EP2854528B8 (https=)
JP (3) JP6352905B2 (https=)
KR (2) KR20200118233A (https=)
CN (1) CN104507308A (https=)
AU (2) AU2013267166A1 (https=)
BR (1) BR112014029954A2 (https=)
CA (2) CA3090268A1 (https=)
EA (1) EA032345B1 (https=)
ES (1) ES2761449T3 (https=)
IL (1) IL236008B (https=)
IN (1) IN2014DN10734A (https=)
MX (2) MX369768B (https=)
NZ (1) NZ702369A (https=)
SG (1) SG11201407880QA (https=)
WO (1) WO2013181639A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
DK3634391T3 (da) * 2017-05-17 2025-03-31 Bpgbio Inc Anvendelse af coenzym q10-formuleringer i behandlingen og forebyggelsen af epidermolysis bullosa
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
ES2809302T3 (es) * 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
JPWO2008069276A1 (ja) * 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
AU2010247800A1 (en) * 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
CN105168135A (zh) * 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.

Also Published As

Publication number Publication date
ES2761449T3 (es) 2020-05-19
MX369768B (es) 2019-11-21
EP2854528B1 (en) 2019-09-18
JP6352905B2 (ja) 2018-07-04
IL236008A0 (en) 2015-02-01
WO2013181639A8 (en) 2014-12-31
HK1208995A1 (en) 2016-03-24
CN104507308A (zh) 2015-04-08
JP2018168164A (ja) 2018-11-01
JP2020183440A (ja) 2020-11-12
KR20150022932A (ko) 2015-03-04
KR102163948B1 (ko) 2020-10-12
IL236008B (en) 2018-08-30
US20220096399A1 (en) 2022-03-31
WO2013181639A1 (en) 2013-12-05
KR20200118233A (ko) 2020-10-14
MX2019013776A (es) 2020-01-30
EP2854528A1 (en) 2015-04-08
EA201492187A1 (ru) 2015-05-29
AU2017202567A1 (en) 2017-05-11
US20170216223A1 (en) 2017-08-03
EP2854528A4 (en) 2016-03-09
BR112014029954A2 (pt) 2017-06-27
US20140017317A1 (en) 2014-01-16
EA032345B1 (ru) 2019-05-31
SG11201407880QA (en) 2014-12-30
JP7225167B2 (ja) 2023-02-20
AU2017202567B2 (en) 2019-06-13
EP2854528B8 (en) 2019-10-23
CA2875150C (en) 2020-10-27
CA2875150A1 (en) 2013-12-05
NZ702369A (en) 2016-12-23
MX2014014492A (es) 2015-05-12
JP2015518056A (ja) 2015-06-25
IN2014DN10734A (https=) 2015-09-04
AU2013267166A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
US20220096399A1 (en) Methods of treatment of solid tumors using coenzyme q10
US20210369645A1 (en) Methods for the treatment of cancer using coenzyme q10 combination therapies
US11452699B2 (en) Method of treating or preventing tumors of the central nervous system
US20200330400A1 (en) Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
HK1208995B (en) Treatment of solid tumors using coenzyme q10

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201113

FZDE Discontinued

Effective date: 20230606